The U.S. Food and Drug Administration’s (FDA’s) broad definition of “misbranding” has created some industry confusion, while the Federal Trade Commission’s (FTC’s) updates to its Health Products Compliance Guidance have done the same.
In light of these recent actions, what challenges are dietary supplement manufacturers now facing?
On this episode, Epstein Becker Green attorneys Jack Wenik, Teddy McCormick, Zach Taylor, and Tracey Gonzalez discuss recent updates to the FDA and FTC guidelines as they apply to dietary supplement manufacturers, as well as new developments with respect to misbranding.
About the Diagnosing Health Care Podcast
What health care and life sciences decision-makers need to lead, comply, and compete. The health care industry is full of high-stakes legal, policy, and regulatory obstacles. And significant opportunities for those prepared to act on them. Diagnosing Health Care® delivers the intelligence executives, general counsel, and administrators need to navigate both. Part of the Epstein Becker Green Insights Network.
Email Notifications
Follow Us
Never miss an episode! Subscribe to Diagnosing Health Care on your preferred platform:
Also on Audible | Deezer | Goodpods | iHeartRadio | PlayerFM | Pocket Casts | YouTube Music
